Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QP002
- Development stage
- Phase 2
- Lead developer
- Nanjing Delova Biotech
- Modality
- Small Molecules, Hydrogel Systems → Drug Delivery Systems
- Administration
- Topical
01
Overview
QP002 is a pharmaceutical drug developed by Nanjing Qingpu Biotechnology. It is being investigated as a topical gel formulation for postoperative analgesia, specifically to manage pain following orthopedic surgeries such as unilateral total hip replacement and hallux valgus correction (bunion surgery). The drug is currently in Phase 2 clinical trials, where its efficacy, safety, and pharmacokinetic characteristics are being evaluated. The precise molecular target or mechanism of action has not been disclosed in public sources. Its development focuses on the nervous system therapeutic area, particularly for acute pain management after surgical procedures[1][9].
Beyond the preview
Go deeper on QP002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QP002.